Is the drug industry spending millions on a made-up disease? Have the latest cancer drugs been overhyped? And why does anyone go to BIO?

We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a discussion of NASH, the purported billion-dollar market opportunity that might be too good to be true, followed by a breakdown of a pair of upcoming conferences — one packed with news and the other not so much. Then comes a lightning round that touches on President Trump’s vague promises, the mystery surrounding a genomics pioneer, and drugs that make you racist.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy